PD-L1 Antibodies for Cancer Immunotherapy via TRIZ Segmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack effective agents to modulate the immune system's checkpoint pathways, particularly targeting Programmed Death-Ligand 1 (PD-L1), which is crucial for activating the immune response in cancer immunotherapy and treating chronic infections.
Innovation Solution
Development of high-affinity, specific antibody molecules that bind to PD-L1, inhibiting its activity without interacting with CD28, CTLA-4, ICOS, or BTLA, and enhancing T-cell activation and tumor antigen presentation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used, then treatment of cancer and infectious diseases is attempted, but effective immune system modulation through checkpoint pathway targeting is lacking
Solution Approach 1:
The antibody molecule is designed with distinct functional segments: variable regions for specific PD-L1 binding and constant regions for effector functions. This segmentation allows the molecule to independently perform antigen recognition and immune modulation, resolving the contradiction between reliable immune modulation and specific target engagement.
Solution Approach 2:
The antibody acts as an intermediary molecule that bridges the gap between the immune system and the PD-L1 checkpoint pathway. By specifically binding to PD-L1, the antibody mediates immune system activation without requiring direct modification of the checkpoint pathway itself, thereby achieving reliable immune modulation with high target specificity.
2Reliability
If high-affinity antibodies binding to PD-L1 are developed, then T-cell activation and tumor antigen presentation are enhanced, but specificity to avoid interaction with CD28, CTLA-4, ICOS, or BTLA must be maintained
Solution Approach 1:
The antibody's variable regions are engineered with specific local qualities (amino acid sequences in CDRs) that confer high affinity for PD-L1 while maintaining exclusivity. This localized optimization of binding properties ensures that the antibody interacts only with the intended target among multiple similar receptors, resolving the contradiction between reliable T-cell activation and specificity across multiple receptor types.
Solution Approach 2:
The antibody design involves precise parameter changes in the variable region sequences, particularly in the complementarity determining regions (CDRs). By optimizing binding parameters such as affinity constants and epitope recognition patterns, the antibody achieves high-specificity binding to PD-L1 while avoiding cross-reactivity with CD28, CTLA-4, ICOS, or BTLA, thereby enhancing T-cell activation with maintained specificity.
3Reliability
If PD-L1 binding affinity is increased to inhibit immune evasion, then tumor-infiltrating lymphocytes increase, but off-target effects on other B7 family members must be avoided
Solution Approach 1:
Instead of designing the antibody to broadly inhibit all B7 family members, the approach inverts the strategy by specifically targeting only PD-L1 while deliberately excluding interactions with other B7 family members like B7.1 and B7.2. This inverted specificity approach ensures reliable inhibition of immune evasion through PD-L1 blockade while avoiding harmful off-target effects on other immunoregulatory molecules.
Data Source
AI summary
Antibody molecules that specifically bind to PD-L1 are disclosed. Combination therapies comprising the anti-PD-L1 antibody molecules are also disclosed. The anti-PD-L1 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious conditions and disorders.